Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Kaj Blennow?

Kaj Blennow

Professor

Sahlgrenska Academy

Direct Phone: +46 ** *** ** **direct phone

Email: k***@***.se

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Sahlgrenska Academy

Sweden

Company Description

The Sahlgrenska Academy is the faculty of health sciences at the University of Gothenburg. Education and research are conducted within the fields of pharmacy, medicine, odontology and health care sciences. About 4000 undergraduate students and 1000 postgraduat... more.

Find other employees at this company (389)

Web References(97 Total References)


Scientific Advisory Board | Cerora

cerora.com [cached]

Kaj Blennow, MD, PhD
Kaj Blennow, MD, PhD


Scientific Advisory Board | Alzheon

www.alzheon.com [cached]

Kaj Blennow, MD, PhD
Professor of Clinical Neurochemistry, University of Gothenburg, Sweden Head of Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden


Resume: Blennow_K | Cerora

cerora.com [cached]

Kaj Blennow
Kaj Blennow, MD, PhD Medical Advisor Kaj Blennow, MD, PhD is a professor at Sahlgrenska University Hospital in Goteborg, Sweden. Dr. Blennow conducts research on the mechanisms behind neurological disorders and over the past twenty (20) years, he has developed biochemical tests for Alzheimer's disease. He is a world-renowned researcher and clinician in both concussion and Alzheimer's disease.


www.alz.org

Kaj Blennow, The Sahlgrenska Academy at University of Gothenburg, Sweden
Kaj Blennow Kaj Blennow


www.psychiatrictimes.com

A recent review article in Alzheimer's and Dementia discusses the current state of cerebrospinal fluid-borne markers for Alzheimer disease.2 Tests that identify proteins in the CSF could be very specific to Alzheimer disease because the fluid directly interacts with brain tissue.3 According to first author, Kaj Blennow, MD, PhD, Professor of Clinical Neurochemistry at the Sahlgrenska University Hospital in Mölndal, Sweden, CSF is potentially better than blood since "a brain protein will be diluted in the larger blood volume, metabolized and degraded.
Blennow explains "They have been evaluated in hundreds of papers and very consistently show that more than 85%-90% of AD (and prodromal AD) cases have low Abeta42 and high total-tau and phospho-tau." Levels of CSF amyloid-beta seem to decrease as post-mortem or biopsied brain levels increase, so it seems that the protein may deposit itself in the brain and while it correspondingly decreases in the fluid. CSF phosphorylated tau levels also correspond with the amount of neurofibrillary tangles found in a later autopsy. In addition, high levels of total tau in the CSF seem to indicate that mild cognitive impairment will quickly progress to full Alzheimer dementia. Unfortunately, the markers seem to be only good in the early stages of the disease. Blennow explains: "it seems that the AD biomarkers reach a plateau very early in disease progression, and thus do not change with progression." Researchers may have another problem with developing a clinical test: the methods being used are not the same in every lab. The development of consistent assays is a high current priority in this field. According to Dr Blennow "what is needed is more work on standardization, both the analytical part and assay production, so that we can get uniform values between labs.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory